Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder

A meta-analysis of individual patient data from 10 double-blind, randomized clinical trials

George I. Papakostas, Madhukar H. Trivedi, Jonathan E. Alpert, Cheryl A. Seifert, Alok Krishen, Elizabeth P. Goodale, Vivian L. Tucker

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The goal of this work was to compare the efficacy of the norepinephrine-dopamine reuptake inhibitor bupropion with the selective serotonin reuptake inhibitors (SSRIs) in the treatment of anxiety symptoms in major depressive disorder (MDD). Ten double-blind, randomized studies, involving a total of 2890 bupropion-, SSRI- or placebo- treated patients were pooled. Anxiety symptoms of depression were defined using the Hamilton depression rating scale (HDRS) Anxiety-Somatization factor (HDRS-AS) score, as well as the Hamilton anxiety scale (HAM-A) score. Both bupropion and the SSRIs led to a comparable degree of improvement in anxiety symptoms, defined using the HDRS-AS score (-3.8 ± 2.8 vs. -3.9 ± 2.8, p = 0.130) or HAM-A score (-8.8 ± 7.2 vs. -9.1 ± 7.0, p = 0.177). There was no consistent difference in the time to anxiolysis between the two treatment groups. In addition, there was no difference in the proportion of bupropion- and SSRI- remitters who continued to experience residual anxiety, defined as a HDRS-AS score >0 at endpoint (69.2% vs. 74.7%, p = 0.081) or a HAM-A score >7 at endpoint (9.5% vs. 8.4%, p = 0.284). Finally, there was no statistically significant difference in the severity of residual anxiety symptoms between bupropion- or SSRI- treated patients with remitted depression, defined using the HDRS-AS (1.15 ± 1.14 vs. 1.25 ± 1.09, p = 0.569), or HAM-A scores at endpoint (3.30 ± 2.89 vs. 3.31 ± 2.89, p = 0.552). Contrary to clinician impression, there does not appear to be any difference in the anxiolytic efficacy of bupropion and the SSRIs when used to treat MDD.

Original languageEnglish (US)
Pages (from-to)134-140
Number of pages7
JournalJournal of Psychiatric Research
Volume42
Issue number2
DOIs
StatePublished - Jan 2008
Externally publishedYes

Fingerprint

Bupropion
Major Depressive Disorder
Serotonin Uptake Inhibitors
Meta-Analysis
Anxiety
Randomized Controlled Trials
Depression
Therapeutics
Dopamine Uptake Inhibitors
Efficacy
Meta-analysis
Clinical Trials
Anti-Anxiety Agents
Double-Blind Method
Norepinephrine
Placebos

Keywords

  • Anxiety
  • Bupropion
  • Depression
  • MDD
  • SSRIs
  • Treatment

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder : A meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. / Papakostas, George I.; Trivedi, Madhukar H.; Alpert, Jonathan E.; Seifert, Cheryl A.; Krishen, Alok; Goodale, Elizabeth P.; Tucker, Vivian L.

In: Journal of Psychiatric Research, Vol. 42, No. 2, 01.2008, p. 134-140.

Research output: Contribution to journalArticle

@article{298e06a9589647fcbff6a245a95787c6,
title = "Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: A meta-analysis of individual patient data from 10 double-blind, randomized clinical trials",
abstract = "The goal of this work was to compare the efficacy of the norepinephrine-dopamine reuptake inhibitor bupropion with the selective serotonin reuptake inhibitors (SSRIs) in the treatment of anxiety symptoms in major depressive disorder (MDD). Ten double-blind, randomized studies, involving a total of 2890 bupropion-, SSRI- or placebo- treated patients were pooled. Anxiety symptoms of depression were defined using the Hamilton depression rating scale (HDRS) Anxiety-Somatization factor (HDRS-AS) score, as well as the Hamilton anxiety scale (HAM-A) score. Both bupropion and the SSRIs led to a comparable degree of improvement in anxiety symptoms, defined using the HDRS-AS score (-3.8 ± 2.8 vs. -3.9 ± 2.8, p = 0.130) or HAM-A score (-8.8 ± 7.2 vs. -9.1 ± 7.0, p = 0.177). There was no consistent difference in the time to anxiolysis between the two treatment groups. In addition, there was no difference in the proportion of bupropion- and SSRI- remitters who continued to experience residual anxiety, defined as a HDRS-AS score >0 at endpoint (69.2{\%} vs. 74.7{\%}, p = 0.081) or a HAM-A score >7 at endpoint (9.5{\%} vs. 8.4{\%}, p = 0.284). Finally, there was no statistically significant difference in the severity of residual anxiety symptoms between bupropion- or SSRI- treated patients with remitted depression, defined using the HDRS-AS (1.15 ± 1.14 vs. 1.25 ± 1.09, p = 0.569), or HAM-A scores at endpoint (3.30 ± 2.89 vs. 3.31 ± 2.89, p = 0.552). Contrary to clinician impression, there does not appear to be any difference in the anxiolytic efficacy of bupropion and the SSRIs when used to treat MDD.",
keywords = "Anxiety, Bupropion, Depression, MDD, SSRIs, Treatment",
author = "Papakostas, {George I.} and Trivedi, {Madhukar H.} and Alpert, {Jonathan E.} and Seifert, {Cheryl A.} and Alok Krishen and Goodale, {Elizabeth P.} and Tucker, {Vivian L.}",
year = "2008",
month = "1",
doi = "10.1016/j.jpsychires.2007.05.012",
language = "English (US)",
volume = "42",
pages = "134--140",
journal = "Journal of Psychiatric Research",
issn = "0022-3956",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder

T2 - A meta-analysis of individual patient data from 10 double-blind, randomized clinical trials

AU - Papakostas, George I.

AU - Trivedi, Madhukar H.

AU - Alpert, Jonathan E.

AU - Seifert, Cheryl A.

AU - Krishen, Alok

AU - Goodale, Elizabeth P.

AU - Tucker, Vivian L.

PY - 2008/1

Y1 - 2008/1

N2 - The goal of this work was to compare the efficacy of the norepinephrine-dopamine reuptake inhibitor bupropion with the selective serotonin reuptake inhibitors (SSRIs) in the treatment of anxiety symptoms in major depressive disorder (MDD). Ten double-blind, randomized studies, involving a total of 2890 bupropion-, SSRI- or placebo- treated patients were pooled. Anxiety symptoms of depression were defined using the Hamilton depression rating scale (HDRS) Anxiety-Somatization factor (HDRS-AS) score, as well as the Hamilton anxiety scale (HAM-A) score. Both bupropion and the SSRIs led to a comparable degree of improvement in anxiety symptoms, defined using the HDRS-AS score (-3.8 ± 2.8 vs. -3.9 ± 2.8, p = 0.130) or HAM-A score (-8.8 ± 7.2 vs. -9.1 ± 7.0, p = 0.177). There was no consistent difference in the time to anxiolysis between the two treatment groups. In addition, there was no difference in the proportion of bupropion- and SSRI- remitters who continued to experience residual anxiety, defined as a HDRS-AS score >0 at endpoint (69.2% vs. 74.7%, p = 0.081) or a HAM-A score >7 at endpoint (9.5% vs. 8.4%, p = 0.284). Finally, there was no statistically significant difference in the severity of residual anxiety symptoms between bupropion- or SSRI- treated patients with remitted depression, defined using the HDRS-AS (1.15 ± 1.14 vs. 1.25 ± 1.09, p = 0.569), or HAM-A scores at endpoint (3.30 ± 2.89 vs. 3.31 ± 2.89, p = 0.552). Contrary to clinician impression, there does not appear to be any difference in the anxiolytic efficacy of bupropion and the SSRIs when used to treat MDD.

AB - The goal of this work was to compare the efficacy of the norepinephrine-dopamine reuptake inhibitor bupropion with the selective serotonin reuptake inhibitors (SSRIs) in the treatment of anxiety symptoms in major depressive disorder (MDD). Ten double-blind, randomized studies, involving a total of 2890 bupropion-, SSRI- or placebo- treated patients were pooled. Anxiety symptoms of depression were defined using the Hamilton depression rating scale (HDRS) Anxiety-Somatization factor (HDRS-AS) score, as well as the Hamilton anxiety scale (HAM-A) score. Both bupropion and the SSRIs led to a comparable degree of improvement in anxiety symptoms, defined using the HDRS-AS score (-3.8 ± 2.8 vs. -3.9 ± 2.8, p = 0.130) or HAM-A score (-8.8 ± 7.2 vs. -9.1 ± 7.0, p = 0.177). There was no consistent difference in the time to anxiolysis between the two treatment groups. In addition, there was no difference in the proportion of bupropion- and SSRI- remitters who continued to experience residual anxiety, defined as a HDRS-AS score >0 at endpoint (69.2% vs. 74.7%, p = 0.081) or a HAM-A score >7 at endpoint (9.5% vs. 8.4%, p = 0.284). Finally, there was no statistically significant difference in the severity of residual anxiety symptoms between bupropion- or SSRI- treated patients with remitted depression, defined using the HDRS-AS (1.15 ± 1.14 vs. 1.25 ± 1.09, p = 0.569), or HAM-A scores at endpoint (3.30 ± 2.89 vs. 3.31 ± 2.89, p = 0.552). Contrary to clinician impression, there does not appear to be any difference in the anxiolytic efficacy of bupropion and the SSRIs when used to treat MDD.

KW - Anxiety

KW - Bupropion

KW - Depression

KW - MDD

KW - SSRIs

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=35848954053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35848954053&partnerID=8YFLogxK

U2 - 10.1016/j.jpsychires.2007.05.012

DO - 10.1016/j.jpsychires.2007.05.012

M3 - Article

VL - 42

SP - 134

EP - 140

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

SN - 0022-3956

IS - 2

ER -